The Vaccine Safety Datalink project

DeStefano, Frank

doi:10.1002/pds.613

Cited by 115 publications

(42 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The design and data collection methods of the VSD have been described in detail [18]. Annually, over 9 million persons are enrolled and computerized data on demographics, immunizations, and medical encounters, including ICD-9 diagnosis codes, are collected.…”

Section: Methodsmentioning

confidence: 99%

Guillain-Barré Syndrome Incidence in a Large United States Cohort (2000–2009)

Shui

Rett²,

Weintraub³

et al. 2012

Neuroepidemiology

View full text Add to dashboard Cite

Background/Aim: We describe the incidence of Guillain-Barré syndrome (GBS) in a large United States cohort. Methods: Between 2000 and 2009, we identified visits with an ICD-9 code for GBS (357.0) from all persons with continuous enrollment for at least 1 year. The primary case definition was restricted to emergency department and inpatient visits. We calculated age-standardized rates and used multivariate Poisson regression to assess variation in rates by sex, age, season and year of diagnosis. We tabulated descriptive characteristics and the positive predictive value (PPV) for a subset of the visits with available medical record review. Results: 1,619 visits with the GBS ICD-9 code were identified from 50,290,898 person-years of observation. After considering the PPV (55%) for record-reviewed visits, the age-standardized incidence rate was approximately 1.72/100,000 person-years. The rate was 40% higher for males and increased by 50% for every 10-year increase in age. The rate was 15% higher in winter and spring compared with summer. Rates were higher in more recent years. Conclusions: GBS rates are higher in males and increase considerably with age. The potential reasons for differences in rates by season and the increased rates in more recent years should be further investigated.

show abstract

Section: Methodsmentioning

confidence: 99%

Guillain-Barré Syndrome Incidence in a Large United States Cohort (2000–2009)

Shui

Rett²,

Weintraub³

et al. 2012

Neuroepidemiology

View full text Add to dashboard Cite

show abstract

“…[7][8][9] The institutional review boards of the 3 MCOs, CDC, and Abt Associates Inc approved the study. The study protocol was developed before data collection in consultation with a panel of external consultants that included autism advocates and experts in autism, child development, toxicology, epidemiology, biostatistics, and vaccine safety.…”

Section: Methodsmentioning

confidence: 99%

Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism

et al. 2010

Self Cite

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT:Most previous research has not revealed an increased risk of autism associated with receipt of thimerosal-containing vaccines. Evidence is limited, however, on the timing of vaccination, especially prenatal exposure, and associations with different subtypes of autism. WHAT THIS STUDY ADDS:This study revealed no increased risk of ASD associated with receipt of thimerosal-containing vaccines. No increased risk was found for subtypes of ASD, including ASD with regression, and prenatal exposure was not associated with a risk of ASD. abstract OBJECTIVE: Exposure to thimerosal, a mercury-containing preservative that is used in vaccines and immunoglobulin preparations, has been hypothesized to be associated with increased risk of autism spectrum disorder (ASD). This study was designed to examine relationships between prenatal and infant ethylmercury exposure from thimerosalcontaining vaccines and/or immunoglobulin preparations and ASD and 2 ASD subcategories: autistic disorder (AD) and ASD with regression. METHODS:A case-control study was conducted in 3 managed care organizations (MCOs) of 256 children with ASD and 752 controls matched by birth year, gender, and MCO. ASD diagnoses were validated through standardized in-person evaluations. Exposure to thimerosal in vaccines and immunoglobulin preparations was determined from electronic immunization registries, medical charts, and parent interviews. Information on potential confounding factors was obtained from the interviews and medical charts. We used conditional logistic regression to assess associations between ASD, AD, and ASD with regression and exposure to ethylmercury during prenatal, birth-to-1 month, birthto-7-month, and birth-to-20-month periods. RESULTS:There were no findings of increased risk for any of the 3 ASD outcomes. The adjusted odds ratios (95% confidence intervals) for ASD associated with a 2-SD increase in ethylmercury exposure were 1.12 (0.83-1.51) for prenatal exposure, 0.88 (0.62-1.26) for exposure from birth to 1 month, 0.60 (0.36 -0.99) for exposure from birth to 7 months, and 0.60 (0.32-0.97) for exposure from birth to 20 months.

show abstract

“…17,18,46 Monitoring and studies continue within VAERS and the VSD. 57 A study of the association of influenza vaccination and GBS in children would be difficult because of the low background incidence of GBS in this age group, 58 and would require a large cohort of children over many years to be able to have the needed power for such a rare event.…”

Section: Discussionmentioning

confidence: 99%